Sanofi agreed to in‑license rovadicitinib, a first‑in‑class dual JAK/ROCK inhibitor developed by Sino Biopharm that just secured approval in China, in a transaction valued north of $1.4 billion. The deal grants Sanofi rights to the molecule outside China and adds a novel mechanism to its inflammation portfolio. Sino Biopharm’s domestic approval and the Sanofi agreement accelerate global development plans: Sanofi will leverage its global regulatory and commercialization footprint to pursue additional indications and registrational studies. The licensing deal signals Big Pharma appetite for China‑originated assets with differentiated mechanisms. Technical note: dual JAK/ROCK inhibition combines immune signaling and cytoskeletal pathway modulation, potentially offering a distinct efficacy and safety profile versus single‑target JAK inhibitors; upcoming global trials will test that hypothesis.